Advances in the anti-Parkinson's disease drugs

QU Wei,PU Xiao-ping
2008-01-01
Abstract:Parkinson's disease(PD)is a common neurodegenerative disorder characterized by progressive loss of nigral dopaminergic neurons and decrease in striatal dopamine levels.For many years,levodopa has been the most popular drug to treat PD patients.However,this agent can induce motor fluctuations and dyskinesias after long- term treatment.Currently,the most promising approaches include the 'neuroprotective' drugs that are capable of blocking or at least slowing down the degenerative process responsible for cellular death;'restorative'strategies in- tended to restore normal brain function;more effective agents for replacing dopamine loss;and symptomatic and an- tidyskinetic drugs that act on neurotransmitters other than dopamine or target brain areas other than the striatum.In addition,some novel drugs with new mechanism,such as the adenosine A_(2A)receptor antagonist and anti-apoptotic drugs are promising in treating PD alone or in combination with other disorders.In this review we will discuss new anti-PD drugs that are widely-used in clinic and drugs in development that target the primary motor disorder in PD.
What problem does this paper attempt to address?